Monopar Therapeutics (MNPR) Enterprise Value (2016 - 2020)
Monopar Therapeutics (MNPR) has disclosed Enterprise Value for 5 consecutive years, with -$18.0 million as the latest value for Q3 2020.
- Quarterly Enterprise Value fell 300.1% to -$18.0 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was -$18.0 million through Sep 2020, down 300.1% year-over-year, with the annual reading at -$13.2 million for FY2019, 91.71% down from the prior year.
- Enterprise Value hit -$18.0 million in Q3 2020 for Monopar Therapeutics, down from -$12.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$2.9 million in Q4 2016 to a low of -$18.0 million in Q3 2020.
- Historically, Enterprise Value has averaged -$8.4 million across 5 years, with a median of -$7.9 million in 2018.
- Biggest five-year swings in Enterprise Value: surged 41.0% in 2019 and later tumbled 300.1% in 2020.
- Year by year, Enterprise Value stood at -$2.9 million in 2016, then tumbled by 212.63% to -$9.0 million in 2017, then increased by 23.26% to -$6.9 million in 2018, then plummeted by 91.71% to -$13.2 million in 2019, then plummeted by 36.09% to -$18.0 million in 2020.
- Business Quant data shows Enterprise Value for MNPR at -$18.0 million in Q3 2020, -$12.5 million in Q2 2020, and -$12.6 million in Q1 2020.